These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 20121565)

  • 21. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries.
    Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE
    Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
    Godman B; Shrank W; Wettermark B; Andersen M; Bishop I; Burkhardt T; Garuolienè K; Kalaba M; Laius O; Joppi R; Sermet C; Schwabe U; Teixeira I; Tulunay FC; Wendykowska K; Zara C; Gustafsson LL
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2470-2494. PubMed ID: 27713363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost driver analysis of statin expenditure on Australia's Pharmaceutical Benefits Scheme.
    Thai LP; Moss JR; Godman B; Vitry AI
    Expert Rev Pharmacoecon Outcomes Res; 2016 Jun; 16(3):419-33. PubMed ID: 26707482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in the utilization of venlafaxine after the introduction of generics in Sweden.
    Godman B; Persson M; Miranda J; Skiöld P; Wettermark B; Barbui C; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Aug; 11(4):383-93. PubMed ID: 23754677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications.
    Godman B; Wettermark B; van Woerkom M; Fraeyman J; Alvarez-Madrazo S; Berg C; Bishop I; Bucsics A; Campbell S; Finlayson AE; Fürst J; Garuoliene K; Herholz H; Kalaba M; Laius O; Piessnegger J; Sermet C; Schwabe U; Vlahović-Palčevski VV; Markovic-Pekovic V; Vončina L; Malinowska K; Zara C; Gustafsson LL
    Front Pharmacol; 2014; 5():106. PubMed ID: 24987370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available.
    Wladysiuk M; Araszkiewicz A; Godman B; Szabert K; Barbui C; Haycox A
    Appl Health Econ Health Policy; 2011 Mar; 9(2):101-10. PubMed ID: 21271749
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of lifting prescribing restrictions for losartan on subsequent sartan utilization patterns in Austria: implications for other countries.
    Bucsics A; Godman B; Burkhardt T; Schmitzer M; Malmström RE
    Expert Rev Pharmacoecon Outcomes Res; 2012 Dec; 12(6):809-19. PubMed ID: 23252361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications.
    Martin A; Godman B; Miranda J; Tilstone J; Saleem N; Olsson E; Acosta A; Restrepo L; Bennie M
    J Comp Eff Res; 2014 Jan; 3(1):41-51. PubMed ID: 24345256
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Policies to enhance prescribing efficiency in europe: findings and future implications.
    Godman B; Shrank W; Andersen M; Berg C; Bishop I; Burkhardt T; Garuoliene K; Herholz H; Joppi R; Kalaba M; Laius O; Lonsdale J; Malmström RE; Martikainen JE; Samaluk V; Sermet C; Schwabe U; Teixeira I; Tilson L; Tulunay FC; Vlahović-Palčevski V; Wendykowska K; Wettermark B; Zara C; Gustafsson LL
    Front Pharmacol; 2010; 1():141. PubMed ID: 21833180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups.
    Sermet C; Andrieu V; Godman B; Van Ganse E; Haycox A; Reynier JP
    Appl Health Econ Health Policy; 2010; 8(1):7-24. PubMed ID: 20038190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.
    Zeng W; Gustafsson LL; Bennie M; Finlayson AE; Godman B
    Expert Rev Pharmacoecon Outcomes Res; 2015 Feb; 15(1):157-69. PubMed ID: 25348709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are prescribing initiatives readily transferable across classes: the case of generic losartan in Scotland?
    Bennie M; Bishop I; Godman B; Campbell S; Miranda J; Finlayson AE; Gustafsson LL
    Qual Prim Care; 2013; 21(1):7-15. PubMed ID: 23735629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of demand-side measures to enhance renin-angiotensin prescribing efficiency in Europe: implications for the future.
    Vončina L; Strizrep T; Godman B; Bennie M; Bishop I; Campbell S; Vlahović-Palčevski V; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):469-79. PubMed ID: 21831028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Twenty-Year Nationwide Trends in Statin Utilization and Expenditure in Denmark.
    Mortensen MB; Falk E; Schmidt M
    Circ Cardiovasc Qual Outcomes; 2017 Jul; 10(7):. PubMed ID: 28698192
    [No Abstract]   [Full Text] [Related]  

  • 36. Statin prescribing in Northern Ireland and England pre and post introduction of the quality and outcomes framework.
    Alabbadi I; Crealey G; Turner K; Rafferty T; Keenan L; Murray P; McElnay JC
    Pharm World Sci; 2010 Feb; 32(1):43-51. PubMed ID: 19882233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries.
    Godman B; Bishop I; Finlayson AE; Campbell S; Kwon HY; Bennie M
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):469-82. PubMed ID: 23977975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of proton pump inhibitors anti-ulcer drugs use in the Araba district primary care area].
    Martínez Gorostiaga J; Echevarría Orella E; Calvo Hernáez B
    Rev Esp Salud Publica; 2018 Aug; 92():. PubMed ID: 30100604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trend analysis of proton pump inhibitor consumption and expenditure: The real-world evidence.
    Ferrara F; Capuozzo M; Celotto V; Ottaiano A; Langella R; Zovi A
    Indian J Gastroenterol; 2024 Jun; 43(3):645-651. PubMed ID: 38231298
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trends in prescribing proton pump inhibitors in Taiwan: 1997 - 2000.
    Chen TJ; Chou LF; Hwang SJ
    Int J Clin Pharmacol Ther; 2003 May; 41(5):207-12. PubMed ID: 12776811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.